Literature DB >> 17180474

Breast cancer local recurrence: risk factors and prognostic relevance of early time to recurrence.

A Neri1, D Marrelli, S Rossi, A De Stefano, F Mariani, G De Marco, S Caruso, G Corso, T Cioppa, E Pinto, F Roviello.   

Abstract

BACKGROUND: Local recurrence occurs in 10%-20% of patients treated with breast-conserving surgery for stage I-II breast cancer. The aim of the present study was to investigate breast cancer local recurrence, potential risk factors, and prognostic impact.
METHODS: A total of 503 patients treated with breast-conserving surgery were included in the study. All patients underwent axillary dissection and postoperative radiotherapy, and all patients had negative margins at pathological examination. Median follow-up was 82 months. Local recurrence was classified as early when it occurred within 2 years from surgery. The risk factors for local recurrence and overall survival were estimated by univariate and multivariate analyses.
RESULTS: Forty-six cases (9.1%) of local recurrence were observed, 11 of which occurred within 24 months of surgery; the other 35, sometime later. Statistically significant risk factors for local recurrence were premenopausal status, peritumoral vascular invasion, multifocality, and absence of estrogen receptors. Independent negative prognostic factors for overall survival at 5 and 10 years were N stage, absence of estrogen receptors, and early time to recurrence. Overall survival at 10 years was 10.0% for patients with early recurrence, 87.5% for patients with late recurrence, and 87.9% for patients without recurrence.
CONCLUSIONS: None of the studied clinicopathological characteristics alone is a determinant for the choice of surgical treatment. Younger patients treated with breast-conserving surgery should receive aggressive postsurgical treatment and should be followed with an intensive follow-up program when metastatic axillary lymph nodes, negative estrogen receptors, or peritumoral vascular invasion are present.

Entities:  

Mesh:

Year:  2007        PMID: 17180474     DOI: 10.1007/s00268-006-0097-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  46 in total

1.  Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases.

Authors:  H S Maki; J L Hoehn
Journal:  Arch Surg       Date:  1989-03

2.  Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06.

Authors:  E R Fisher; S Anderson; E Tan-Chiu; B Fisher; L Eaton; N Wolmark
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

3.  Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival.

Authors: 
Journal:  Cancer Control       Date:  1997-07       Impact factor: 3.302

4.  [Conservative treatment of multifocal breast cancer: a comparative study].

Authors:  C Nos; D Bourgeois; C Darles; B Asselain; F Campana; B Zafrani; J C Durand; K Clough
Journal:  Bull Cancer       Date:  1999-02       Impact factor: 1.276

5.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.

Authors:  J A Jacobson; D N Danforth; K H Cowan; T d'Angelo; S M Steinberg; L Pierce; M E Lippman; A S Lichter; E Glatstein; P Okunieff
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

Review 6.  Young age and outcome for women with early-stage invasive breast carcinoma.

Authors:  Ping Zhou; Abram Recht
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

7.  Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Authors:  Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

8.  Age as prognostic factor in premenopausal breast carcinoma.

Authors:  A de la Rochefordiere; B Asselain; F Campana; S M Scholl; J Fenton; J R Vilcoq; J C Durand; P Pouillart; H Magdelenat; A Fourquet
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

9.  Risk factors in breast-conservation therapy.

Authors:  J Borger; H Kemperman; A Hart; H Peterse; J van Dongen; H Bartelink
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

10.  Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma.

Authors:  C G Clemente; P Boracchi; S Andreola; M Del Vecchio; P Veronesi; F O Rilke
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

View more
  10 in total

1.  Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement.

Authors:  Danielle J Fitzpatrick; Christine S Lai; Robert F Parkyn; David Walters; Vladimir Humeniuk; David C A Walsh
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

2.  Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

Authors:  Annemieke Witteveen; Annemiek B G Kwast; Gabe S Sonke; Maarten J IJzerman; Sabine Siesling
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

3.  Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence.

Authors:  Soojin Park; Wonshik Han; Jongjin Kim; Min Kyoon Kim; Eunshin Lee; Tae-Kyung Yoo; Han-Byoel Lee; Young Joon Kang; Yun-Gyoung Kim; Hyeong-Gon Moon; Dong-Young Noh
Journal:  J Breast Cancer       Date:  2015-06-26       Impact factor: 3.588

4.  Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital.

Authors:  Chagkrit Ditsatham; Areewan Somwangprasert; Kirati Watcharachan; Phanchaporn Wongmaneerung; Jiraporn Khorana
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-03-18

5.  Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.

Authors:  Alexandre Lafourcade; Mathilde His; Laura Baglietto; Marie-Christine Boutron-Ruault; Laure Dossus; Virginie Rondeau
Journal:  BMC Cancer       Date:  2018-02-09       Impact factor: 4.430

6.  [Early Recurrence of Breast Cancer after the Primary Treatment: Analysis of Clinicopathological and Radiological Predictive Factors].

Authors:  Sun Geun Yun; Yeong Yi An; Sung Hun Kim; Bong Joo Kang
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-02-18

7.  A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification.

Authors:  Raffaella Massafra; Maria Colomba Comes; Samantha Bove; Vittorio Didonna; Sergio Diotaiuti; Francesco Giotta; Agnese Latorre; Daniele La Forgia; Annalisa Nardone; Domenico Pomarico; Cosmo Maurizio Ressa; Alessandro Rizzo; Pasquale Tamborra; Alfredo Zito; Vito Lorusso; Annarita Fanizzi
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

8.  Short term recurrence and survival rate of breast cancer patients post surgical treatment; north borneo experience.

Authors:  Raynee Kumilau; Firdaus Hayati; Jerry Es Liew; Siti Zubaidah Sharif; Nik Amin Sahid Nik Lah
Journal:  Ann Med Surg (Lond)       Date:  2022-09-02

9.  Do all patients require radiotherapy after breast-conserving surgery?

Authors:  Anita R Skandarajah; G Bruce Mann
Journal:  Cancers (Basel)       Date:  2010-04-28       Impact factor: 6.639

10.  A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions.

Authors:  Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Wonshik Han; Kyubo Kim; Eui Kyu Chie; In-Ae Park; Young Tae Kim; Dong-Young Noh; Sung Whan Ha; Yung-Jue Bang
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.